Topotecan in cervical cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 6, 2007, Pages 1215-1223

  Ackermann, S ^a   Beckmann, M W ^a   Thiel, F ^a   Bogenrieder, T ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b GLAXOSMITHKLINE   (Germany)

Author keywords

Cervical cancer; Cisplatin; Radiotherapy; Topotecan; Weekly administration

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PACLITAXEL; TOPOTECAN; VINBLASTINE;

ADJUVANT THERAPY; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEVER; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; RADIOTHERAPY, ADJUVANT; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 35948938874     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01003.x     Document Type: Review

References (48)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006 56: 106 30.
2. Damasus-Awatai G, Freeman-Wang T. Human papilloma virus and cervical screening. Curr Opin Obstet Gynecol 2003 15: 473 7.
3. Friedlander M, Grogan M. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 2002 7: 342 7.
4. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999 340: 1154 61.
5. Brader KR, Morris M, Levenback C, Levy L, Lucas KR, Gershenson DM. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol 1998 16: 1879 84.
6. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995 22: 67 75.
7. Fiorica JV. The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol 2003 90: S16 21.
8. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003 361: 2235 42.
9. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002 8: 641 61.
10. Noda K, Sasaki H, Yamamoto K et al. Phase II trial of topotecan for cervical cancer of the uterus [abstract]. Proc ASCO 1996 15.
11. Abu-Rustum NR, Lee S, Massad LS. Topotecan for recurrent cervical cancer after platinum-based therapy. Int J Gynecol Cancer 2000 10: 285 8.
12. Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000 77: 446 9.
13. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2001 81: 213 5.
14. Tiersten AD, Selleck MJ, Hershman DL et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 2004 92: 635 8.
15. Fiorica J, Holloway R, Ndubisi B et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol 2002 85: 89 94.
16. Long HJ III., Bundy BN, Grendys EC Jr. et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005 23: 4626 33.
17. Monk BJ, Huang HQ, Cella D, Long HJ III. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005 23: 4617 25.
18. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999 340: 1137 43.
19. Noel G, Mazeron JJ. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. Cisplatin, radiation, and adjuvant hysterectomy for bulky stage IB cervical carcinoma. Cancer Radiother 1999 3: 345 7.
20. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999 340: 1144 53.
21. Peters GJ, Van der Wilt CL, Van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000 87: 227 53.
22. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999 17: 1339 48.
23. Rein DT, Kurbacher CM. The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects. Anticancer Drugs 2001 12: 787 95.
24. Kim JH, Kim SH, Kolozsvary A, Khil MS. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 1992 22: 515 8.
25. Lamond JP, Wang M, Kinsella TJ, Boothman DA. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int J Radiat Oncol Biol Phys 1996 36: 361 8.
26. Graham MV, Jahanzeb M, Dresler C, Cooper J, Emami B, Mortimer J. Preliminary results of a phase I study of topotecan plus thoracic radiotherapy for locally advanced non-small-cell lung cancer (NSCLCA) [abstract]. Proc ASCO 1994 13. A1132.
27. Graham MV, Jahanzeb M, Dresler CM, Cooper JD, Emami B, Mortimer JE. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 1996 36: 1215 20.
28. Forouzannia A, Schiller J, Berlin J et al. A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung Cancer 2004 44: 111 9.
29. Bell MC, Davidson SA, Mathis JM, Ampil F. Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial. Gynecol Oncol 2001 80: 128 31.
30. Dunton CJ, King SA, Neufeld J et al. Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecol Oncol 2002 85: 185 7.
31. Moore DH. Neoadjuvant chemotherapy for cervical cancer. Expert Opin Pharmacother 2003 4: 859 67.
32. Bloss JD, Lucci JA III., DiSaia PJ et al. A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix. Gynecol Oncol 1995 59: 105 10.
33. Omura GA, Brady MF, Look KY et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 2003 21: 2843 8.
34. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985 3: 1079 85.
35. Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 2003 9: 425 32.
36. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 334: 1 6.
37. Curtin JP, Blessing JA, Webster KD et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2001 19: 1275 8.
38. Morris M, Brader KR, Levenback C et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998 16: 1094 8.
39. Lacava JA, Leone BA, Machiavelli M et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 1997 15: 604 9.
40. Goedhals L, Bezwoda WR, Abratt RP, Rathgeb F, Goebel KJ, Wurst W. Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug. Int J Clin Pharmacol Ther 1995 33: 664 9.
41. Mutch DG, Bloss JD. Gemcitabine in cervical cancer. Gynecol Oncol 2003 90: S8 15.
42. Omura GA, Blessing JA, Vaccarello L et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997 15: 165 71.
43. Kumar L, Pokharel YH, Kumar S, Singh R, Rath GK, Kochupillai V. Single agent versus combination chemotherapy in recurrent cervical cancer. J Obstet Gynaecol Res 1998 24: 401 9.
44. Bloss JD, Blessing JA, Behrens BC et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2002 20: 1832 7.
45. Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2004 22: 3113 9.
46. Sit AS, Kelley JL, Gallion HH, Kunschner AJ, Edwards RP. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Invest 2004 22: 368 73.
47. Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 2005 7: 419 34.
48. O'Brien M, Ciuleanu T, Tsekov H et al. O-157 survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC. Lung Cancer 2005 49: S54.